Terms, Conditions and Disclaimers

I. Limitation of Liability: The U.S. Government, NIH, and/or NCATS and their employees and contractors assume no liability for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed herein and do not represent that use of such information, apparatus, product, or process would not infringe on privately owned rights. No warranty is provided that PaVe-GT Resources, including the NCATS PaVe-GT Site, will be uninterrupted or error-free, or that defects in PaVe-GT Resources will be corrected, that any information contained on or transmitted through the Site or Resources are complete, accurate, or current, that user or other information will be completely secure from authorized access or disclosure, or that any information is free of viruses, applicable to other gene therapy projects or other rogue programming.

II. Disclaimer of Scientific and Medical Advice: You understand and acknowledge that all users of the NCATS PaVe-GT Site and PaVe GT Resources are responsible for their own choices in drug development, including vector design, preclinical and clinical study design and execution, regulatory strategy, and oversight. All scientific and medical information contained in the PaVe-GT Resources, including but not limited to information in media content, study results, project documents, regulatory submissions, scientific protocols and methods, communications with regulators, publications, presentations, sample templates and curated list of additional resources are for informational purposes only, and are not intended to be a substitute for independent, professional drug development and clinical development judgment or advice. NCATS and/or NIH emphasizes that details, strategies and choices described in the PaVe-GT Resources are not general recommendations, and may be inappropriate, problematic, inefficient, unsafe, or otherwise undesirable for other gene therapy programs or disease indications to adopt, including specific choices and information related to vector design, optimization study design, IND-enabling studies, regulatory approach, dosing, eligibility criteria, and clinical protocols. Users of PaVe-GT Resources must do their own due diligence. Advice on the treatment or care of any patient should always be obtained through consultation with a physician who has examined that patient and is familiar with that patient’s medical history.

III. Non-Endorsement: All PaVe-GT Resources and any materials that the NCATS PaVe-GT Site provides are for information purposes only and do not represent endorsement by or an official position of NCATS, the NIH, or any Federal agency.

IV. Third-Party Information and Rights: Some documents hosted or listed on the NCATS PaVe-GT Site are associated with private companies (e.g., academic publishers) and other organizations (e.g., nonprofits, other agencies). Accordingly, other parties may retain all rights to publish or reproduce these documents or to allow others to do so, and may be protected under the U.S. and foreign Copyright laws. Permission to reproduce may be required.

V. Attribution: Information and Resources that are created by or for the US government on this site is within the public domain. Public domain information on the PaVe-GT webpages may be freely distributed and copied. However, it is requested that in any subsequent use of this work, NIH be given appropriate acknowledgment.

Pave-GT Resources
Rare Pediatric Disease (RPD) Designation Request for AAV9-hPCCA

This pdf file contains the RPD designation request for AAV9-hPCCA (NCATSBL-0746) and associated communications between NCATS and FDA OOPD.

Orphan Drug Designation (ODD) Request for AAV9-hPCCA

This pdf file contains the ODD request for AAV9-hPCCA (NCATSBL-0746) and associated communications between NCATS and FDA OOPD.

Sign-up for PaVe-GT updates.


National Institutes of Health